LIH and Luxembourg hospitals contribute to assessing the safety of potential COVID-19 treatments
The Centre Hospitalier de Luxembourg (CHL), and specifically its National Infectious Disease Department (Service National des Maladies Infectieuses – SNMI) and Intensive Care Unit, the Hôpitaux Robert Schuman (HRS), and the Clinical and Epidemiological Investigation Centre (CIEC) of the Luxembourg Institute of Health (LIH) contributed to the results of the European clinical trial “DisCoVeRy”. Although the findings, which were published in December 2020 in “New England Journal of Medicine”, do not support the use of the investigated drugs for the treatment of more severe forms of COVID-19, they represent a step forward in the understanding of the disease and in ensuring patient safety. These results feed into the broader international trial “Solidarity”, supporting its outcomes.
Strengthening the Digital Health and Artificial Intelligence axis at LIH
Dr Guy Fagherazzi, Group Leader of the Deep Digital Phenotyping Research Unit at the LIH Department Population Health (DoPH), will ensure the leadership of DoPH effective January 1st 2021. His appointment will further deepen the integration of digital data and Artificial Intelligence (AI) within the department’s and the institute’s research activities.
Translating research into clinical applications
The COVID-19 pandemic has shown that conducting strong translational research is key to combating the coronavirus. By leveraging cutting edge laboratory techniques to study patient samples, translational research quickly pivots laboratory discoveries into new therapies for patients, in a process known as the bench-to-bedside approach. Luxembourg has established excellent transversal and translational research, spanning several research topics and disease areas and integrating the results to provide holistic and meaningful insights that can tangibly improve clinical outcomes for patients.
International prize “Prix du Fonds Léon et Henri Fredericq” awarded to LIH researcher
Dr Andy Chevigné, Group Leader of the Immuno-Pharmacology and Interactomics research group at the LIH Department of Infection and Immunity (DII), was rewarded for his outstanding contribution to the fields of allergology and molecular pharmacology through the bestowal of the “Prix du Fonds Léon et Henri Fredericq” by the Royal Academy of Science, Letters and Fine Arts of Belgium.
[Press release] New insights into Glioblastoma invasiveness
Researchers from the NORLUX Neuro-Oncology Laboratory at the LIH Department of Oncology (DONC) explored the molecular mechanisms responsible for the ability of Glioblastoma (GBM) to infiltrate and spread to healthy brain tissue. They brought forward the novel role of protein ZFAND3 in promoting the transcription of several genes that stimulate the invasion of GBM cells in the surrounding parenchyma, the functional tissue in the brain. The findings, which carry significant implications for the development of novel therapeutic strategies against GBM, were published in the international journal Nature Communications.
Cross-border collaborations to improve cancer treatment
On December 9th, Medical & Bio Decision (MBD) announced the setup of a joint laboratory for precision medicine tailored to cancer patients, in collaboration with the Luxembourg Institute of Health (LIH) and the Integrated Biobank of Luxembourg (IBBL).
[Press release] Luxembourg researchers receive prestigious international award
Dr Andy Chevigné and Dr Martyna Szpakowska from the LIH Department of Infection and Immunity (DII) were rewarded for their outstanding contribution to molecular pharmacology during a virtual ceremony on Tuesday, December 8th, in the presence of Frank Vandenbroucke, Belgian Minister of Public Health and Social Affairs, and of representatives of pharmaceutical companies and healthcare hubs. The Galien Prize is traditionally organised in Belgium and Luxembourg by Roularta HealthCare on a yearly basis and crowns the most significant discoveries in the fields of pharmacology, drug development and medical devices.
Solidarity in COVID-19 times
On Thursday, November 26th 2020, the Luxembourg Institute of Health (LIH) had the pleasure of welcoming the Director of the André Losch Foundation to its premises in Strassen for a visit of its Clinical and Epidemiological Investigation Centre (CIEC). The event also provided an opportunity to discuss the status of the COVID-19 projects coordinated by LIH and supported by the Foundation.
Results of the European Commission Horizon 2020 “ERAvsCORONA Action Plan”
The European Commission confirmed its support to three new research projects involving the Luxembourg Institute of Health (LIH) submitted within the framework of the Horizon 2020 call “Innovative and rapid health-related approaches to respond to COVID-19 and to deliver quick results for society for a higher level of preparedness of health systems” (SC1-PHE-CORONAVIRUS-2020-2). The projects aim to foster the development of a novel diagnostic test and improve the cooperation between European and international cohorts to strengthen the response to the pandemic. The total funding for the studies amounts to EUR 26.2 million.